Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma

NCT02562625 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT02562625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02562625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Terminated
Start date
August 11, 2016
Completion date
October 31, 2021
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma